June 2026: Anthropic confidentially filed its first IPO paperwork, then released a public S-1 this week showing revenue of $16.3 billion for the first half of 2026 and its first operating profit in the second quarter. The bullish case is clear: revenue had surged, cash reserves were enormous and the company appeared to be turning AI demand into a real enterprise business.¹

As customers expanded: The company’s supporters argue that early AI pilots understate the opportunity. More than 11,900 customers were spending at least $100,000 annually by September 30, up from more than 950 a year earlier; existing customers collectively spent roughly nine times more than a year before. The thesis is that companies will keep discovering work worth automating or augmenting, rather than treating Claude as a one-off software purchase.²

Alongside coding, Anthropic moved into biology: It launched Claude Science in beta, opened a molecular biology lab, acquired Coefficient Bio in a $400 million stock deal and highlighted adoption among pharmaceutical groups. Its filing casts life sciences as both a social mission and a premium new market: AI, it says, could “bring cures for major diseases within reach.”³

Monday’s public prospectus sharpened the trade-off. Founders asked investors not to view a share purchase “in purely transactional terms,” pitching advanced AI as a historic project while also cataloguing catastrophic and existential risks. The company’s public-benefit structure is meant to signal mission discipline, yet its founders retain 50.1% of shareholder voting power through a special Class F share—an arrangement with “no direct public company precedent.”⁴⁵

The financial clock is now ticking: Analysts point to a sharp third-quarter deceleration after explosive earlier growth, just as Anthropic has accumulated at least roughly $850 billion in long-term compute and infrastructure commitments, potentially nearing $1 trillion. As one analyst put it, “Growth is not optional for this company. The contracts assume it.”⁶

Ahead of the expected IPO: Market anxiety over AI infrastructure spending has made the pitch harder. Yet supporters still see 1,300% annual sales growth, 900% net revenue retention and an implied 85% gross margin as proof of a potentially generational company. The central question is whether those metrics represent a durable flywheel—or an unusually favorable moment before the bills arrive.⁷